Therefore, given the enrichment of TMEM189 in human cancers and poor clinical benefit with high TMEM189 expression, we propose TMEM189 as a very promising therapeutic target than GPX4 for activating ferroptosis in human cancers. Here, PEDS1 is linked to cancer.